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cataracts, diabetic retinopathy, age-related macular
degeneration and cytomegalovirus retinitis. CONCLU-
SIONS: For research that requires a self-administered
measure of vision-related QOL, the NEI-VFQ-25 appears
to be the optimum choice. It has demonstrated accept-
able psychometric properties across several QOL
domains with minimal respondent burden.
PES13
COMPARING THE QUALITY OF LIFE EFFECTS
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ASSESSED BY THE DERMATOLOGY LIFE
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OBJECTIVES: The objective of this study was to assess
and descriptively compare the quality of life (QOL)
effects of hyperhidrosis (HH), as measured by the Der-
matology Life Quality Index (DLQI), relative to other
dermatological conditions with published DLQI scores.
METHODS: Primary hyperhidrosis patients asking for
care at the Dermatology Clinic of the University of
Würzburg completed the DLQI as part of a research study
to assess the quality of life burden resulting from 
hyperhidrosis. Patients were categorized by main site of
involvement (i.e. axillary, palmar, other) to identify any
focal location-dependent differences. In addition, a liter-
ature search was performed to identify published reports
of DLQI scores for hyperhidrosis and other dermatolog-
ical conditions. Mean DLQI total scores observed in this
clinic cohort were compared with those for other derma-
tological conditions to determine the relative QOL effects
of hyperhidrosis. RESULTS: DLQI data were collected
from 345 hyperhidrosis patients in the dermatology
clinic. Forty-two published reports of mean DLQI total
scores for dermatological conditions, including three for
hyperhidrosis, were identiﬁed. Mean DLQI total scores
for hyperhidrosis ranged from 9.9–18 indicating signiﬁ-
cant quality of life impairment. By focal location of
hyperhidrosis, reported ranges for mean DLQI total
scores were: palmar (8.8–18), axillary (10–17), facial
(12.5), and mixed (9.2–15.5). Overall, hyperhidrosis was
associated with similar or greater impairment than other
dermatological conditions including psoriasis (4.5–13.9),
eczema (4.1–16.2), and acne (4.3–9.3). Similar mean
DLQI total scores and ranges were observed for both axil-
lary and palmar hyperhidrosis. CONCLUSIONS: This
review suggests that the QOL effects of hyperhidrosis as
assessed by the DLQI are comparable to, and in most
cases greater than, other dermatological conditions for
which DLQI data are available.
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OBJECTIVES: Quality of life enables patients to assess
the different consequences of the disease and/or treat-
ment. Skin disorders have a strong impact on the patient’s
physical and psychological well-being and the numerous
quality of life studies carried out among adults are here
to conﬁrm this. However, very few studies have been 
performed to assess the quality of life in children. This 
is mainly attributable to the fact that there is a lack of 
questionnaires to do this. METHOD: A speciﬁc scale
developed by Professor A. FINLAY (C-DLQI—Children-
Dermatology Life Quality Index) is completed by each
child before starting the course of treatment at Avène
Hydrotherapy Center, after three weeks of treatment,
after three months and after 6 months. RESULTS: Every
year, Avène Hydrotherapy Center welcomes a growing
number of children suffering from chronic dermatosis. It
thus seemed relevant to assess the quality of life of these
children (4–15 years old). The following initial analysis
has been obtained from the 30 ﬁrst questionnaires 
completed upon inclusion and after 3 months. The DLQI
score upon inclusion was 23.58 and 11.60 after 3
months. The results show an improvement in the patient’s
quality of life 3 months after the hydrotherapy course 
of treatment. This difference is statistically signiﬁcant 
(p = 0.010). After 3 weeks of treatment, the C-DLQI score
was 20.3 (p = 20.32). CONCLUSION: These results
clearly show that even some time after the end of the
hydrotherapy course of treatment, quality of life in chil-
dren suffering from chronic dermatosis continues to be
improved.
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OBJECTIVE: The objective of our work was to translate
the Cardiff Acne Disability Index (CADI) into French,
with careful attention to the linguistic aspects and the 
cultural context of the French patients. METHOD: The
CADI is a scale devised by Prof. R.J. Motley and A. Finlay
of Cardiff to assess the disability caused by acne. This
questionnaire has been used in numerous studies to eval-
uate the consequences of the disease in daily life or the
effects of different treatments. Following international
methodological recommendations, the CADI scale was
translated in a standardized way consisting of forward
translation, quality control, backward translation, and a
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pretest. RESULTS: With the author’s approval, the ques-
tionnaire was translated from English to French by two
independent translators. The two versions were compared
and a few non signiﬁcant differences were noted. The
translations were discussed and reviewed, item-by-item,
until a consensus was achieved: version 3. The version 3
was critically reviewed by a bilingual expert version 4. A
bilingual translator back-translated version 4 in version
4b which after discussion with the main author has been
accepted as expressing the questions in the same way as
the original version. CONCLUSION: To make sure that
the translation is consistent with our objective, the pretest
analysis is ongoing among 20 patients. For a large-scale
validation, this questionnaire will be remitted during a
clinical trial on a new therapeutic strategy in more than
80 patients.
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. This is conﬁrmed by the
large number of quality of life studies that exist. Psoria-
sis and atopic dermatitis are the two most frequents
chronic dermatosis, therefore we estimated relevant to
cross-compare the patients’ quality of life. OBJECTIVES:
The Avène Dermatological Hydrotherapy Centre, which
welcomes over 2500 patients a year, offers real unity 
conditions of time and location in order to realise a 
cross-analysis. METHOD: A generic scale (SF-12) and a
speciﬁc scale (DLQI—Dermatology Life Quality Index)
are completed by each patient at their arrival at the Avène
Dermatological Hydrotherapy Centre. The completed
questionnaires were returned by post. RESULTS: In the
analysed population, the mean age is respectively 40.5
years old versus 55.5y.o. for patients suffering atopic der-
matitis (n = 141) versus psoriasis (n = 54) (p < 0.00001).
The DLQI score at inclusion is 37.84 for atopic dermati-
tis patients, 32.81 for psoriasis patients. Concerning the
SF-12, the results consisted of 2 scores: mental (MCS-12)
and physical (PCS-12). At inclusion the atopic dermatitis
patients scores were: PCS-12 = 47.5 & MCS-12 = 33.8,
the psoriasis patients scores were: PCS-12 = 46.3 & MCS-
12 = 39.0. If those two scales’ results show evidence of
an impairment in patients’ quality of life, no difference is
demonstrated between the two groups. CONCLUSION:
Those ﬁrst results demonstrated an equal impairment in
quality of life for patients suffering either from atopic 
dermatitis than psoriasis.
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. This is conﬁrmed by the
large number of quality of life studies that exist. It is clear
that dermatological diseases affect not only the life of the
children but also that of his/her family. OBJECTIVES:
The Avène Dermatological Hydrotherapy Center, wel-
comes over 2500 patients a year suffering from skin 
diseases. The objective of the study is to demonstrate the
relevance of the long term effects of hydrotherapy treat-
ments on patients quality of life. METHOD: A generic
scale (SF-12) and a speciﬁc scale (DLQI—Dermatology
Life Quality Index) are completed by each patient at their
arrival at the Avène Dermatological Hydrotherapy Center
(inclusion), at the end of hydrotherapy cares (3 weeks)
and at 3 and 6 months. The completed questionnaires
were returned by post. RESULTS: In this ﬁrst analysis,
the ﬁrst 30 patients suffering from the three following
conditions: psoriasis, atopic dermatitis were taken into
account and analysed at inclusion and at the 6 months
after the hydrotherapy cares. The DLQI score at inclu-
sion is 32.1. At 6 months the DLQI score is 24.2. These
ﬁrst results show evidence of an improvement of patients’
quality of life 6 months after hydrotherapy treatments 
(p < 0.02). CONCLUSION: These ﬁrst results show evi-
dence of an improvement of patients’ quality of life 6
months after hydrotherapy treatments.
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OBJECTIVE: To evaluate the effect of psoriasis on
quality of life of patients in Spain. MEHOD: Four thou-
sand ﬁve hundred anonymous questionnaires (comprised
of two scales: the Psoriasis Disability Index (PDI) plus 10
questions concerning treatment and evolution of psoria-
sis) were sent, via a Psoriasis Patient Support Group
(AccionPsoriasis). RESULTS: Nineteen hundred ques-
tionnaires were returned (June 2002): response rate 42%.
An analysis of the ﬁrst 810 questionnaires was realised.
The sex ratio Men (M)/Women(W) was 49/51. Mean age:
42 years. Mean age of diagnosis: 21.8 years. The average
to the total score was 8.47 (s.d. 7.2 rank 0 to 39) i.e.
18.82 (s.d: 17.2) when reported to a scale of 0 to 100.
Signiﬁcative difference was observed between M and W
for the global handicap score 20.73 vs 16.95 p < 0.002.
Two groups was identiﬁed: pousée de psoriasis (84%),
